Evopoint Biosciences
China - Beijing
BiotechnologyFocus: Next-generation antibody-drug conjugates (ADCs), and targeted protein degradation (TPD) drugs
Evopoint Biosciences is a life sciences company focused on Next-generation antibody-drug conjugates (ADCs), and targeted protein degradation (TPD) drugs.
OncologyInfectious DiseasesUnknownMetabolic DiseasesClinical
Funding Stage
PUBLIC
Open Jobs
6
Pipeline & Clinical Trials
XNW4107
Bacterial InfectionsClinical Trials (1)
NCT04801043To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.
Phase 1XNW4107, Imipenem/Cilastatin
Bacterial InfectionsClinical Trials (1)
NCT04802863Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects
Phase 1XNW7201 tablets
Advanced Solid TumorsClinical Trials (1)
NCT03901950Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors
Phase 1XNW4107
Bacterial InfectionsClinical Trials (1)
NCT04482569Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin
Phase 1XNW4107, Imipenem/Cilastatin
Bacterial InfectionsClinical Trials (1)
NCT04787562Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function
Phase 1XNW3009
GoutClinical Trials (1)
NCT04040907The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject
Phase 1Phase 1/2
Clinical Trials (1)
NCT06702995Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
Phase 1/2XNW34017
Advanced Solid TumorsClinical Trials (1)
NCT07327294A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT06792435XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Phase 1/2XNW5004 tablets
Advanced TumorClinical Trials (1)
NCT06558513To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors
Phase 1/2XNW28012
Advanced Solid TumorsClinical Trials (1)
NCT06799637Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments
Phase 1/2XNW29016
Tumor, SolidClinical Trials (1)
NCT06987500A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment
Phase 1/2XNW5004
CarcinomaClinical Trials (1)
NCT06022757Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Phase 1/2XNW5004 tablets
Relapsed/Refractory Peripheral T Cell LymphomaClinical Trials (1)
NCT06702605To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
Phase 2XNW5004 ; Chidamide placebo
Relapsed/Refractory Peripheral T Cell LymphomaClinical Trials (1)
NCT06776952A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Phase 3Combination of Imipenem/Cilastatin and XNW4107
Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial PneumoniaClinical Trials (1)
NCT05204563Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)
Phase 3Combination of Imipenem/Cilastatin and XNW4107
Complicated Urinary Tract Infection Including Acute PyelonephritisClinical Trials (1)
NCT05204368Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)
Phase 3Open Jobs (6)
CRA/SCRA
Shanghai, Beijing, Guangzhou, Jinan, Taiyuan, Shenyang, Xi'an, Hefei, Nanjing, Hangzhou, Chongqing, Chengdu, Nanning
Clinical10mo ago
Medicinal Chemistry Researcher
Suzhou
Preliminary Research1y ago
Medical Manager
Shanghai/Chengdu
Clinical1y ago
Process Equipment Engineer
Suzhou
Factory1y ago
Production Engineer
Suzhou
Factory1y ago
Marketing HRBP
Shanghai
Functional1y ago
Interview Prep Quick Facts
Portfolio: 17 clinical trials
Top TAs: Oncology
Open Roles: 6 active jobs